Copyright © 2003 by Institute of Pharmacology
Polish Academy of Sciences
Polish Journal of Pharmacology
Pol. J. Pharmacol., 2003, 55, 741746
ISSN 1230-6002
DEFICIT OF ENDOGENOUS KYNURENIC ACID
IN THE FRONTAL CORTEX OF RATS WITH A GENETIC
FORM OF ABSENCE EPILEPSY
Rafa³ M. Kamiñski1,*, El¿bieta Zieliñska1, Andrzej Dekundy1,,
Gilles van Luijtelaar2, Waldemar A. Turski1,3,#
Department of Toxicology, Institute of Agricultural Medicine, Jaczewskiego 2, PL 20-950 Lublin, Poland,
Department of Biological Psychology, Nijmegen Institute for Cognition and Information, University of Nijmegen,
P.O. Box 9104, 6500 HE Nijmegen, The Netherlands, !Department of Pharmacology and Toxicology, Medical
University, Jaczewskiego 8, PL 20-090 Lublin, Poland
*Present address: Epilepsy Research Section, National
Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, MD 20892, USA; VPresent address: Department of Pharmacology, Merz
Pharmaceuticals, Frankfurt am Main, D-60318, Germany
Deficit of endogenous kynurenic acid in the frontal cortex of rats with
a genetic form of absence epilepsy. R.M. KAMIÑSKI, E. ZIELIÑSKA,
A. DEKUNDY, G. VAN LUIJTELAAR, W.A. TURSKI. Pol. J. Pharmacol.,
2003, 55, 741–746.
The present studies sought to determine the concentrations of endogenous kynurenic acid (KYNA) and to measure the activity of kynurenine aminotransferases (KAT) I and II in the discrete brain regions of 3- and 6-month
old WAG/Rij rats, a genetic model of absence epilepsy. Analogues experiments were performed using age-matched ACI rats, which served as a nonepileptic control.
The age-dependent increase in KYNA concentration in the frontal cortex
of WAG/Rij rats was considerably reduced in comparison to what was found
in ACI rats. Consequently, the concentration of KYNA in the frontal cortex
of epileptic rats was significantly lower than in non-epileptic controls. There
were no such strain differences in other brain regions. The activities of KAT
I and II also showed age-dependent increase with an exception for KAT II in
the frontal cortex.
Our data suggest that selective deficits of endogenous KYNA may account for increased excitability in the frontal cortex, which in turn may lead
to the development of spontaneous spike-wave discharges in WAG/Rij rats.
Key words: kynurenic acid, aminotransferase, WAG/Rij rats, ACI rats,
absence epilepsy, genetic models
correspondence; e-mail: turskiwa@asklepios.am.lublin.pl
R.M. Kamiñski, E. Zieliñska, A. Dekundy, G. van Luijtelaar, W.A. Turski
INTRODUCTION
Kynurenic acid (KYNA) is endogenously synthesized from tryptophan via the kynurenine pathway by kynurenine aminotransferases (KAT) I and
II. KYNA is a broad spectrum antagonist of glutamate receptors and it may bind to the glycine site of
the N-methyl-D-aspartate (NMDA) receptor with
relatively high affinity. It also binds with similar affinity to the nicotinic receptors containing the a7
subunit (for reviews see [30, 34–36]).
Glutamatergic neurotransmission plays a pivotal role in the pathogenesis of epilepsy and antagonists of glutamate receptors are powerful anticonvulsants [3, 37]. In line with this, KYNA and its
synthetic analogues are generally efficacious anticonvulsants in a variety of models of experimental
epilepsy [9, 17, 39, 41]. Moreover, reduction of
KYNA levels increases vulnerability to excitotoxic
insults, whereas elevation of KYNA content has an
opposite effect [29, 45, 46].
A significant role of glutamate receptors has
also been postulated for non-convulsive epilepsy
[4, 5, 16, 25, 26]. In WAG/Rij rats, serving as
a well-validated, genetic model of absence epilepsy
[42, 43], spontaneous spike-wave discharges (SWD)
can be inhibited by KYNA administration. Moreover, KYNA blocks NMDA-induced potentiation of
SWD in these rats [25, 26]. The above-mentioned
findings prompted us to examine the concentrations
of endogenous KYNA and the activity of KAT in
the discrete brain regions of WAG/Rij rats.
MATERIALS and METHODS
Animals
The analyses were performed in the parts of the
brain where SWD are either evoked [23] or modulated [6]. The measurements were carried out at the
age when WAG/Rij rats (i) begin to develop SWD
(3 months) and (ii) display hundreds of SWD per
day (6 months) [2]. Analogous experiments were
performed in age-matched ACI rats, which are virtually devoid of SWD [15]. Such experimental design allows studying not only the age- and straindependent changes but also their interaction. Since
only the 6 months old WAG/Rij rats show SWD,
while the other groups do not, the interaction can
be tentatively interpreted as that the biochemical
changes are related to the presence of SWD. This
paradigm has been previously employed in other
studies [19, 20]. The number of animals in each
742
strain/age-matched group ranged from 3 to 6. Experimental procedures were in agreement with European Communities Council Directive (86/609/EEC)
and were approved by the local Ethics Committee.
Determination of KYNA concentration
Animals were sacrificed by decapitation and
their brains were rapidly removed from the scull.
The frontal cortex, striatum and thalamus were dissected and immediately frozen for further studies.
KYNA levels were estimated according to the
modified method of Turski et al. [40]. Tissue material was homogenized with 1 ml of water by ultrasonication and centrifuged (20000 rpm, 10 min).
Subsequently, 10 ml of 50% trichloroacatic acid and
100 ml of 1 M HCl were added to each sample of
the obtained supernatant. Denatured protein was removed by centrifugation and the resulting supernatant was applied to the columns containing cation-exchange resin (Dowex 50 W+: 200–400 mesh)
prewashed with 0.1 M HCl. Then, the columns were
washed with 1ml of 0.1 M HCl and 1ml of water,
and the fraction containing KYNA was eluted with
2 ml of water. Eluate was subjected to HPLC and
KYNA was detected fluorometrically (Hewlett
Packard 1050 HPLC system: ESA catecholamine
HR-80, 3 mm, C18 reversed-phase column, flow
rate of 1.0 ml/min, excitation 344 nm, emission 398
nm) according to the method of Shibata [32].
Determination of KAT I and KAT II activities
KAT I and KAT II activities were assayed according to the method of Guidetti et al. [12] with
modification. Tissue was homogenized (1:10 w/v) in
5 mM Tris-acetate buffer, pH 8.0, containing 50 mM
pyridoxal-phosphate and 10 mM 2-mercaptoethanol.
The resulting homogenate was dialyzed overnight at
8°C, using cellulose membrane dialysis tubing,
against 4 l of the same buffer. Active samples contained the enzyme preparation with reaction mixture
containing 2 mM L-kynurenine, 1 mM pyruvate, 70
mM pyridoxal-5’-phosphate, 150 mM Tris-acetate
buffer pH of 7.0 (KAT II) or 150 mM Tris-acetate
buffer pH 9.5 (KAT I) in a total volume of 0.2 ml. In
KAT II assay a KAT I inhibitor, glutamine (final
concentration: 2 mM), was added to each sample.
Blank samples containing heat-deactivated enzyme
(100°C for 10 min) and active samples were incubated at 37°C for 24 h. Transfer of the samples to an
ice-bath and the addition of 10 ml of 50% trichloroacetic acid and 100 ml of 1 M HCl terminated the
reaction. The denatured proteins were removed by
Pol. J. Pharmacol., 2003, 55, 741–746
=>'*62') ) ' ?;@6 ( 6 7
RESULTS
The content of KYNA in the frontal cortex (F..0
= 20.3, p < 0.001), striatum (F..< = 15.4, p < 0.01)
and thalamus (F..0 = 33.3, p < 0.001) increased in
an age-dependent manner (Fig. 1A, B, C). Only in
the frontal cortex a significant strain difference (F..0
= 9.5, p < 0.01) and strain times age interaction
(F..0 = 7.4, p < 0.05) were observed (Fig. 1A). Outcomes of the post hoc tests showed that there was
only a significant increase in the content of KYNA
in the frontal cortex from 3 to 6 months in ACI rats,
not in WAG/Rij rats (Fig. 1A, B, C). Moreover, the
6-month-old ACI rats had higher levels of KYNA
(p < 0.01) than all other groups, including the agematched WAG/Rij rats (Fig. 1A).
The activities of KAT I and KAT II are presented in Table 1. The two-way ANOVA revealed
significant age-dependent increases of KAT I activity in the frontal cortex (F..: = 5.2, p < 0.05) and
thalamus (F..: = 10.1, p < 0.01); no strain effects
were found. Likewise, the in vitro activity of KAT
II measured in samples from frontal cortex and
thalamus did not differ between the WAG/Rij and
ACI rats. There was, however, an age-dependent
increase in KAT II activity in the thalamus (F../ =
12.5, p < 0.01), but not in the frontal cortex.
DISCUSSION
The present study demonstrates an age-dependent
increase in the content of KYNA in the discrete
brain regions of epileptic WAG/Rij and non-epileptic ACI rats. These results are consistent with pre-
77' .: !0
KYNA (pmol/g of tissue)
The results obtained from the assays were compared separately for each brain region with the use
of two-way analysis of variance (ANOVA), where
age and strain of rats were used as independent factors. The two-way ANOVA was followed by the
Bonferroni t-test for group comparisons.
150
*, u
3-month-old
6-month-old
100
50
0
–
ACI
–
–
WAG –
B) Striatum
KYNA (pmol/g of tissue)
Statistics
A) Frontal cortex
200
3-month-old
*
6-month-old
150
*
100
50
0
–
ACI
–
–
WAG –
C) Thalamus
KYNA (pmol/g of tissue)
centrifugation and the supernatant was applied to
a Dowex 50 W+ column and quantified by HPLC.
Protein content was determined spectrophotometrically in small aliquots of the respective enzyme preparations according to the method of
Lowry et al. [21]. The final results were expressed
as the amount of KYNA (pmol) synthesized by 1 mg
of protein during 1 h of incubation (pmol/h/mg).
250
3-month-old
200
*
*
6-month-old
150
100
50
0
–
ACI
–
–
WAG –
Fig. 1. The levels of endogenous kynurenic acid (KYNA) in the
frontal cortex (A), striatum (B) and thalamus (C) of WAG/Rij
and ACI rats. Each bar represents the mean ± SEM (pmol/g of
wet weight). Number of animals used in these experiments was
as follows: 3- and 6-month-old ACI rats (n = 3 per group),
3- and 6-month-old WAG/Rij rats (n = 6 per group). * p < 0.05
vs. 3-month-old same strain rats, K p < 0.05 vs. vs. 6-month-old
WAG/Rij rats (Bonferroni t-test)
743
R.M. Kamiñski, E. Zieliñska, A. Dekundy, G. van Luijtelaar, W.A. Turski
Table 1. In vitro activity of kynurenine aminotransferase (KAT) I and II obtained from the frontal cortex and thalamus of WAG/Rij
and ACI rats. The results are expressed as means ± SEM and represent the amount of KYNA (pmol) synthesized by 1 mg of protein
during 1 h of incubation (pmol/h/mg). The increase in KAT I activity in the frontal cortex (F1,13 = 5.2, p < 0.05) and thalamus (F1,13 =
10.1, p < 0.01) was age-dependent (two-way ANOVA). KAT II showed an age-dependent increase, but it reached statistical significance only in the thalamus (F1,14 = 12.5, p < 0.01). * p < 0.05 vs. 3-month-old the same strain rats (Bonferroni t-test)
Age and strain
KAT I (pmol/h/mg)
KAT II (pmol/h/mg)
Frontal cortex
Thalamus
Frontal cortex
Thalamus
3-month-old ACI (n = 3)
7.9 ± 0.7
15.8 ± 2.1
12.4 ± 1.1
31.6 ± 2.4
6-month-old ACI (n = 3)
17.2 ± 2.7
20.7 ± 4.3
21.2 ± 3.0
62.7 ± 11.6*
3-month-old WAG/Rij (n = 4)
13.5 ± 0.9
12.1 ± 1.6
17.2 ± 0.5
37.5 ± 4.9
6-month-old WAG/Rij (n = 5)
21.2 ± 5.9
23.5 ± 2.3*
27.6 ± 9.1
55.9 ± 7.0
viously reported data from other rat strains [11, 24],
thus, such age-depended increase in KYNA concentration could be considered as a more general
feature. Interestingly, selectively in the frontal cortex of 6 months old WAG/Rij rats, this increase was
absent. Therefore, it seems that genetically epileptic rats have lower levels of KYNA in the frontal
cortex than age-matched ACI rats, whereas no
difference was found in 3-month-old rats of both
strains. It is important to underline that only
6 months old WAG/Rij rats display several hundreds of spontaneous SWD per day, while agematched ACI rats and 3 months old WAG/Rij rats
have no or much less SWD [2, 15].
Ample data show that neuronal excitability and
seizure activity can be dampened by increased concentration of KYNA, resulting from either exogenous application or enhanced endogenous production [9, 27, 39, 41, 45, 46]. KYNA (50–500 nmol)
injected icv inhibits spontaneous [26] and NMDAenhanced SWD [25] in WAG/Rij rats. Local administration of KYNA (5 mM) to a slice preparation with intact thalamocortical circuitry also completely abolishes spindle-like oscillations, resembling those seen in electroencephalogram (EEG)
during absence seizures [38]. More recent studies
performed on similar preparations obtained from
WAG/Rij rats also confirm the importance of
NMDA-mediated events in the generation of rhythmic thalamocortical oscillations [5]. It should be
noted, however, that the effective concentrations of
KYNA in the above-mentioned experiments were
much higher than those established in the present
study. As such, the possible role of endogenous
KYNA in controlling epileptic phenomena should
be further scrutinized. Nevertheless, these findings
suggest that KYNA could be an important factor
involved in suppression of cortical excitability.
744
The frontal cortex, striatum and thalamus are
key structures for the development and maintenance of SWD hallmarking absence epilepsy [1, 4, 23,
33]. The present study shows selective reduction of
KYNA concentration in the frontal cortex of WAG/
Rij rats at an age when they display large number
of spontaneous SWD [2]. In contrast, there was no
such difference in the striatum and thalamus of
either epileptic or non-epileptic rats. Several pieces
of evidence suggest that neuronal hyperexcitability
in the frontal cortex seems to have critical importance for the initiation of SWD [4, 5, 22, 33]. Indeed, using non-linear association analysis of the
EEG signals recorded in vivo from multiple cortical
and thalamic sites, it has recently been demonstrated that spontaneous SWD developing in WAG/Rij
rats originate from the frontal cortex [23]. Moreover, stimulation of the sensorimotor cortex by
NMDA application produces responses that spread
much more widely in rats with a genetic form of
absence epilepsy (GAERS) than those seen in control rats [28]. These observations correspond well
with the theory developed by Steriade and Contreras [31], suggesting a dominant role of the neocortex in generation of SWD. Moreover, a hyperexcitable cortex is a prerequisite for the transformation
from sleep spindles to SWD [18]. Therefore, it could
be hypothesized that selective reduction of KYNA
content in the frontal cortex may account, at least in
part, for the development of SWD in WAG/Rij rats.
Both strains of rats displayed age-dependent increase in KAT I activity in samples obtained from
the frontal cortex and thalamus. Similar changes in
KAT II were also found in the samples obtained
from the thalamus. Finally, KAT II activity in the
frontal cortex also showed an age-dependent in-
Pol. J. Pharmacol., 2003, 55, 741–746
=>'*62') ) ' ?;@6 ( 6 7
crease, however, this effect did not reach statistical
significance.
The results obtained in the KAT activity assays
should be interpreted with caution, even though
they showed some degree of correlation with the
endogenous KYNA levels. In vitro assays of KAT
reflect only the maximal capability of these enzymes to synthesize KYNA under artificial conditions. It should be underlined that in vivo activity of
KAT enzymes is regulated by a number of factors
[10, 12, 44] and that in vitro KAT activity does not
necessarily correlate with in vivo KYNA levels [11].
Nevertheless, the lack of significant, age-dependent
increase in KAT II activity in the frontal cortex is
intriguing. It has been previously established that
KAT II is primarily responsible for the synthesis of
endogenous KYNA [12]. Therefore, we may suggest that the observed deficit of KYNA might be, at
least partially, related to enzymatic dysfunction of
KAT II in the frontal cortex.
Additionally, compromised cellular energy metabolism has been shown to have a negative impact
on both in vitro and in vivo KYNA production [13,
14, 31]. Metabolic dysregulation and increased energy metabolism have also been shown in GAERS.
Thus, it was proposed that metabolic deficits may
underlie the occurrence of SWD in this genetic
model of absence epilepsy [7, 8]. Perhaps disturbed
neuronal metabolism could also be a factor responsible for the observed deficit of endogenous KYNA
production in epileptic WAG/Rij rats.
The present results suggest a possible contribution of kynurenine pathway dysfunction to the generation of SWD in WAG/Rij rats. Even though the
interpretation of these results might be hampered
by a limited number of experiments, they may initiate further research focused on unveiling the role of
KYNA in absence epilepsy.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
REFERENCES
1. Coenen A.M., Drinkenburg W.H., Inoue M., van Luijtelaar E.L.: Genetic models of absence epilepsy, with
emphasis on the WAG/Rij strain of rats. Epilepsy
Res., 1992, 12, 75–86.
2. Coenen A.M., van Luijtelaar E.L.: The WAG/Rij rat
model for absence epilepsy: age and sex factors. Epilepsy Res., 1987, 1, 297–301.
3. Czuczwar S.J. Perspectives for the use of excitatory
amino acid ionotropic receptor antagonists as antiepileptic drugs. Pol. J. Pharmacol., 2000, 52, 67–70.
4. Danober L., Deransart C., Depaulis A., Vergnes M.,
Marescaux C.: Pathophysiological mechanisms of ge-
77' .: !0
16.
17.
18.
netic absence epilepsy in the rat. Prog. Neurobiol.,
1998, 55, 27–57.
D’Arcangelo G., D’Antuono M., Biagini G., Warren R.,
Tancredi V., Avoli M.: Thalamocortical oscillations in
a genetic model of absence seizures. Eur. J. Neurosci.,
2002, 16, 2383–2393.
de Bruin N.M., van Luijtelaar E.L., Cools A.R., Ellenbroek B.A.: Dopamine characteristics in rat genotypes
with distinct susceptibility to epileptic activity: apomorphine-induced stereotyped gnawing and novelty/
amphetamine-induced locomotor stimulation. Behav.
Pharmacol., 2001, 12, 517–525.
Dufour F., Nalecz K.A., Nalecz M.J., Nehlig A.:
Metabolic approach of absence seizures in a genetic
model of absence epilepsy, the GAERS: study of the
leucine-glutamate cycle. J. Neurosci. Res., 2001, 66,
923–930.
Dutuit M., Didier-Bazes M., Vergnes M., Mutin M.,
Conjard A., Akaoka H., Belin M.F., Touret M.: Specific alteration in the expression of glial fibrillary
acidic protein, glutamate dehydrogenase, and glutamine synthetase in rats with genetic absence epilepsy.
Glia, 2000, 32, 15–24.
Foster A.C., Vezzani A., French E.D., Schwarcz R.:
Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic
acid. Neurosci. Lett., 1984, 48, 273–278.
Gramsbergen J.B., Hodgkins P.S., Rassoulpour A.,
Turski W.A., Guidetti P., Schwarcz R.: Brain-specific
modulation of kynurenic acid synthesis in the rat.
J. Neurochem., 1997, 69, 290–298.
Gramsbergen J.B., Schmidt W., Turski W.A., Schwarcz
R.: Age-related changes in kynurenic acid production
in rat brain. Brain Res., 1992, 588, 1–5.
Guidetti P., Okuno E., Schwarcz R.: Characterization
of rat brain kynurenine aminotransferases I and II.
J. Neurosci. Res., 1997, 50, 457–465.
Hodgkins P.S., Schwarcz R.: Metabolic control of kynurenic acid formation in the rat brain. Develop. Neurosci., 1998, 20, 408–416.
Hodgkins P.S., Wu H.Q., Zielke H.R., Schwarcz R.:
2-Oxoacids regulate kynurenic acid production in the
rat brain: studies in vitro and in vivo. J. Neurochem.,
1999, 72, 643–651.
Inoue M., Peeters B.W., van Luijtelaar E.L., Vossen
J.M., Coenen A.M.: Spontaneous occurrence of spikewave discharges in five inbred strains of rats. Physiol.
Behav., 1990, 48, 199–201.
Kamiñski R.M., van Rijn C.M., Turski W.A., Czuczwar S.J., van Luijtelaar G.: AMPA and GABA(B)
receptor antagonists and their interaction in rats with
a genetic form of absence epilepsy. Eur. J. Pharmacol.,
2001, 430, 251–259.
Kiœ J., Czuczwar M., Zieliñska E., Bojar I., Czuczwar
S.J., Turski W.A.: Kynurenic acid does not protect
against nicotine-induced seizures in mice. Pol. J. Pharmacol., 2000, 52, 477–480.
Kostopoulos G.K. Spike-and-wave discharges of absence seizures as a transformation of sleep spindles:
745
R.M. Kamiñski, E. Zieliñska, A. Dekundy, G. van Luijtelaar, W.A. Turski
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
746
the continuing development of a hypothesis. Clin.
Neurophysiol., 2000, 111, Suppl. 2, S27–S38.
Lasoñ W., Przew³ocka B., van Luijtelaar G., Coenen
A.: Proenkephalin and prodynorphin mRNA level in
brain of rats with absence epilepsy. Neuropeptides,
1994, 27, 343–347.
Lasoñ W., Przew³ocka B., van Luijtelaar E.L., Coenen
A.M., Przew³ocki R.: Endogenous opioid peptides in
brain and pituitary of rats with absence epilepsy. Neuropeptides, 1992, 21, 147–152.
Lowry O.H., Rosebrough N.J., Farr A.L., Randall
R.J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem., 1951, 193, 265–275.
Luhmann H.J., Mittmann T., van Luijtelaar G., Heinemann U.: Impairment of intracortical GABAergic inhibition in a rat model of absence epilepsy. Epilepsy
Res., 1995, 22, 43–51.
Meeren H.K., Pijn J.P., van Luijtelaar E.L., Coenen
A.M., Lopes da Silva F.H.: Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J. Neurosci., 2002, 22, 1480–1495.
Moroni F., Russi P., Carla V., Lombardi G.: Kynurenic
acid is present in the rat brain and its content increases
during development and aging processes. Neurosci.
Lett., 1988, 94, 145–150.
Peeters B.W., Ramakers G.M., Ellenbroek B.A., Vossen J.M., Coenen A.M.: Interactions between NMDA
and nonNMDA receptors in nonconvulsive epilepsy
in the WAG/Rij inbred strain. Brain Res. Bull., 1994,
33, 715–718.
Peeters B.W., Ramakers G.M., Vossen J.M., Coenen
A.M.: The WAG/Rij rat model for nonconvulsive absence epilepsy: involvement of nonNMDA receptors.
Brain Res. Bull., 1994, 33, 709–713.
Poeggeler B., Rassoulpour A., Guidetti P., Wu H.Q.,
Schwarcz R.: Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing
rat striatum. Develop. Neurosci., 1998, 20, 146–153.
Pumain R., Louvel J., Gastard M., Kurcewicz I., Vergnes M.: Responses to N-methyl-D-aspartate are enhanced in rats with petit mal-like seizures. J. Neural
Transm. Suppl., 1992, 35, 97–108.
Scharfman H.E., Ofer A.: Pretreatment with L-kynurenine, the precursor to the excitatory amino acid antagonist kynurenic acid, suppresses epileptiform activity in combined entorhinal/hippocampal slices. Neurosci. Lett., 1997, 224, 115–118.
Schwarcz R., Pellicciari R.: Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther., 2002, 303, 1–10.
Schwarcz R., Poeggeler B., Rassoulpour A., CeresoliBorroni G., Hodgkins P.S.: Regulation of kynurenic
acid levels in the developing rat brain. Amino Acids,
1998, 14, 243–249.
Shibata K.: Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity,
by high-performance liquid chromatography. J. Chromatogr., 1988, 430, 376–380.
33. Steriade M., Contreras D.: Spike-wave complexes and
fast components of cortically generated seizures. I. Role
of neocortex and thalamus. J. Neurophysiol., 1998, 80,
1439–1455.
34. Stone T.W.: Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert. Opin. Investig. Drugs,
2001, 10, 633–645.
35. Stone T.W.: Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol., 2001, 64, 185–218.
36. Stone T.W., Darlington L.G.: Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov., 2002, 1, 609–620.
37. Œwi¹der M., KuŸniar H., Kleinrok Z., Czuczwar S.J.:
Influence of LY 300164, an AMPA/kainate receptor
antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in
mice. Pol. J. Pharmacol., 2003, 55, 103–107.
38. Tancredi V., Biagini G., D’Antuono M., Louvel J., Pumain R., Avoli M.: Spindle-like thalamocortical synchronization in a rat brain slice preparation. J. Neurophysiol., 2000, 84, 1093–1097.
39. Turski W.A., Dziki M., Urbañska E., CalderazzoFilho L.S., Cavalheiro E.A.: Seizures induced by aminooxyacetic acid in mice: pharmacological characteristics. Synapse, 1991, 7, 173–180.
40. Turski W.A., Gramsbergen J.B., Traitler H., Schwarcz
R.: Rat brain slices produce and liberate kynurenic
acid upon exposure to L-kynurenine. J. Neurochem.,
1989, 52, 1629–1636.
41. Turski W.A., Urbañska E., Dziki M., Parada-Turska J.,
Ikonomidou C.: Excitatory amino acid antagonists
protect mice against seizures induced by bicuculline.
Brain Res., 1990, 514, 131–134.
42. van Luijtelaar E.L., Coenen A.M.: Two types of electrocortical paroxysms in an inbred strain of rats. Neurosci. Lett., 1986, 70, 393–397.
43. van Luijtelaar E.L.J.M., Drinkenburg W.H.I.M., Smirnova G.P., van Rijn C.M., Coenen A.M.L.: Rat models
of genetic absence epilepsy: what do EEG spike-wave
discharges tell us about drug effects. Meth. Find. Exp.
Clin. Pharmacol., 2002, 24(D), 65–70.
44. Wu H.Q., Baran H., Ungerstedt U., Schwarcz R.:
Kynurenic acid in the quinolinate-lesioned rat hippocampus: studies in vitro and in vivo. Eur. J. Neurosci.,
1992, 4, 1264–1270.
45. Wu H.Q., Guidetti P., Goodman J.H., Varasi M.,
Ceresoli-Borroni G., Speciale C., Scharfman H.E.,
Schwarcz R.: Kynurenergic manipulations influence
excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience,
2000, 97, 243–251.
46. Wu H.Q., Lee S.C., Scharfman H.E., Schwarcz R.: L-4chlorokynurenine attenuates kainate-induced seizures
and lesions in the rat. Exp. Neurol., 2002, 177, 222–232.
Received: August 1, 2003; in revised form: September 25,
2003.
Pol. J. Pharmacol., 2003, 55, 741–746